Related Experiment Videos

Statin therapy and diabetic skin

S Cakmak1, U Gül, M Gönül

  • 1Ministry of Health, Ankara Numune Education and Research Hospital, Dermatology Clinic, Ankara, Turkey. seraycakmak@yahoo.com

Advances in Therapy
|January 29, 2008
PubMed
Abstract

Insights

Statins and diabetes alter skin lipid synthesis, affecting hair follicles and sebaceous glands. This study investigated these histopathological changes in mice.

Area of Science:

  • Dermatology
  • Endocrinology
  • Pharmacology

Background:

  • Statins are primary medications for lowering cholesterol.
  • Diabetes mellitus can cause various skin complications.
  • The impact of statin therapy on skin histopathology, particularly in diabetic individuals, requires further investigation.

Purpose of the Study:

  • To investigate the histopathological effects of statin therapy on the skin of normal and diabetic mice.
  • To compare skin changes induced by statins in the presence and absence of diabetes.

Main Methods:

  • 45 Swiss albino mice were divided into control, statin-treated control, diabetic, and statin-treated diabetic groups.
  • Diabetes was induced using streptozocin; simvastatin was administered intraperitoneally.
  • Skin samples underwent histopathological examination using hematoxylin and eosin staining.

Main Results:

  • No significant differences were observed in epidermal or dermal thickness or proliferative activity across groups.
  • Cystic dilatations in hair follicle infundibula were noted in statin-treated control, diabetic, and statin-treated diabetic groups.
  • Distorted and smaller sebaceous glands were observed in the statin-treated control, diabetic, and statin-treated diabetic groups.

Conclusions:

  • Statin therapy and diabetes independently or collectively alter lipid synthesis within sebaceous glands.
  • These findings suggest a potential mechanism for skin-related side effects associated with statin use, especially in diabetic patients.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Diabetic Foot Ulcer01:31

Diabetic Foot Ulcer

Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...